Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?
NCT ID: NCT06761209
Last Updated: 2025-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2022-07-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis
NCT05473403
Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis
NCT03711669
Autoimmune Hepatitis Cohort in China
NCT05785793
A Study on Factors of Biochemical Response in Autoimmune Hepatitis
NCT06356506
Presence of Circulating Cluster of Differentiation 4 Positive 28 Null T Helper Lymphocytes(CD4+CD28-) in Patients With Autoimmune Hemolytic Anemia.
NCT05711264
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients from the Guadeloupean constitutive center of rare diseases (CCRD Filfoie) and from the Saint-Antoine hospital will be retrospectively analyzed, and new patients will be prospectively followed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
acute or chronic Auto-Immune Hepatitis patients
For the study, a blood sample will be collected from the patient in order to build up a serological library which allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease
blood sampling
For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sampling
For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient followed at Hôpital Saint-Antoine or treated for HAI or in Guadeloupe within the framework of the CCRD Filfoie for an acute or chronic AIH under immunosuppressive treatment
* Patient affiliate or beneficiary of a social security scheme
* Free, informed and written consent signed by the patient and the investigator
Exclusion Criteria
* Viral hepatitis: viruses A to E, Epstein-Barr virus, cytomegalovirus and herpes simplex virus
* Isolated primary biliary cholangitis
* Isolated primary sclerosing cholangitis
* Drug-induced liver injury
* Wilson disease
* Alcoholic hepatitis
* Hemochromatosis
* Sickle cell disease and heart liver
* Non-alcoholic steato-hepatitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de la Guadeloupe
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Moana Lemoinne, doctor
Role: PRINCIPAL_INVESTIGATOR
chu de pointe à pitre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital of Saint-Antoine
Paris, France, France
CHU de Pointe-à Pitre
Pointe à Pitre, Guadeloupe, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sara LEMOINNE, Doctor
Role: backup
Role: backup
Moana GELU-SIMEON, Doctor
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A02908-31
Identifier Type: OTHER
Identifier Source: secondary_id
PAP_RIPH2_2020/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.